1
Country: USA | Funding: $443.6M
Spero Therapeutics develops medications for patients suffering from rare diseases and multidrug-resistant bacterial infections. Its lead drug, the antibiotic Tebipenem HBr, is an oral carbapenem being developed for the treatment of complicated urinary tract infections, including pyelonephritis. If approved, Tebipenem, which has already successfully completed Phase 3 clinical trials, will be the first oral carbapenem for the treatment of this disease. Carbapenems are an important subclass of antibiotics for the treatment of infections caused by drug-resistant Gram-negative bacteria. Carbapenems have become the standard of care for many infections caused by multidrug-resistant Gram-negative bacteria, but are currently only available as intravenous formulations for this indication.
Spero Therapeutics develops medications for patients suffering from rare diseases and multidrug-resistant bacterial infections. Its lead drug, the antibiotic Tebipenem HBr, is an oral carbapenem being developed for the treatment of complicated urinary tract infections, including pyelonephritis. If approved, Tebipenem, which has already successfully completed Phase 3 clinical trials, will be the first oral carbapenem for the treatment of this disease. Carbapenems are an important subclass of antibiotics for the treatment of infections caused by drug-resistant Gram-negative bacteria. Carbapenems have become the standard of care for many infections caused by multidrug-resistant Gram-negative bacteria, but are currently only available as intravenous formulations for this indication.
2
Country: Netherlands | Funding: €96.1M
Micreos is a developer of phage technology for targeted control of bacteria. Micreos’ big idea is to use enzymes made by bacteriophages to selectively take out bacteria without drug resistance.
Micreos is a developer of phage technology for targeted control of bacteria. Micreos’ big idea is to use enzymes made by bacteriophages to selectively take out bacteria without drug resistance.
3
Country: Australia | Funding: $82.6M
Botanix Pharmaceuticals intends to improve the lives of patients suffering from serious skin diseases including acne, psoriasis and atopic dermatitis using a novel therapeutic and advanced transdermal drug delivery system.
Botanix Pharmaceuticals intends to improve the lives of patients suffering from serious skin diseases including acne, psoriasis and atopic dermatitis using a novel therapeutic and advanced transdermal drug delivery system.
4
Country: USA | Funding: $81.7M
Aridis is a biopharmaceutical company focused on the development of human antibodies for hospital-related infections
Aridis is a biopharmaceutical company focused on the development of human antibodies for hospital-related infections
5
Country: USA | Funding: $147.3K
NovoBiotic Pharmaceuticals is a biotechnology company focused on the discovery and development of new drugs from natural sources.
NovoBiotic Pharmaceuticals is a biotechnology company focused on the discovery and development of new drugs from natural sources.
6
Country: Switzerland | Funding: €71.4K
Pattern’s Digital Culture technology will deliver pathogen identification (ID) and antibiotic susceptibility test (AST) results together within four hours.
Pattern’s Digital Culture technology will deliver pathogen identification (ID) and antibiotic susceptibility test (AST) results together within four hours.
